Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bonviva for prevention of glucocorticoid-induced osteoporosis
NCT00545051Phase 4Completed
- Sponsor
- Roche
- Start
- May 2006
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in glucocorticoid-induced osteoporosis (GIOP) comparing Ibandronate with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12. Started May 2006; status: completed.
02
Drugs
ibandronic acid
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT00545051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00545051.